Grace Therapeutics, Inc. (GRCE) stock

GRCENasdaqPharmaceutical PreparationsFiscal year ends March 31

Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30

$1.81+0.00 (0.00%)

Close on Nov 13, 2026Market cap $38.08MP/E –Yield –

Grace Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Grace Therapeutics's price to sales ratio was 0.4× on Jul 29, 2022.

Period	Period end	Value	Change (pts)
2022	Jul 29, 2022	0.4×	−278.0
2021	Jul 30, 2021	278.4×	–

See a number that looks wrong?